Target Name: CD38
NCBI ID: G952
Review Report on CD38 Target / Biomarker Content of Review Report on CD38 Target / Biomarker
CD38
Other Name(s): CD38 antigen (p45) | 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase | ADPRC1 | Lymphocyte differentiation antigen CD38 | ADP-ribosyl cyclase 1 | CD38 antigen | CD38 variant 1

CD38 Antigen as a Drug Target and Biomarker: A Promising Approach for the Treatment of Inflammatory Diseases

CD38 antigen (p45) is a protein that is expressed in various tissues and cells, including immune cells, nerve cells, and epithelial cells. It is a member of the immunoglobulin superfamily and has been implicated in various biological processes, including immune surveillance, inflammation, and tissue repair. In recent years, researchers have discovered that CD38 plays a critical role in the regulation of immune responses and has become a focus of interest in the development of new treatments for inflammatory diseases.

CD38 Antigen as a Drug Target

CD38 antigen has been identified as a potential drug target due to its unique structure and its involvement in various signaling pathways. One of the key advantages of CD38 is its ability to interact with multiple signaling pathways, including the T cell signaling pathway. CD38 has been shown to play a critical role in the regulation of T cell development, activation, and differentiation, as well as in the regulation of immune cell function.

CD38 has been shown to interact with various signaling pathways, including the T cell signaling pathway.

One of the key advantages of CD38 is its ability to interact with multiple signaling pathways, including the T cell signaling pathway. CD38 has been shown to play a critical role in the regulation of T cell development, activation, and differentiation, as well as in the regulation of immune cell function.

CD38 has also been shown to interact with various signaling pathways related to inflammation, including the production of pro-inflammatory cytokines. This suggests that CD38 may play a critical role in the regulation of inflammatory responses.

CD38 as a Biomarker

CD38 antigen has also been used as a biomarker for the evaluation of various diseases, including cancer, autoimmune diseases, and inflammatory diseases. For example, researchers have shown that high levels of CD38 antigen are associated with an increased risk of cancer, including breast and ovarian cancer.

In addition, CD38 has also been used as a biomarker for the evaluation of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Studies have shown that individuals with rheumatoid arthritis or multiple sclerosis have lower levels of CD38 antigen compared to healthy individuals.

CD38 has also been shown to be a potential biomarker for inflammatory diseases, such as Crohn's disease and ulcerative colitis. Studies have shown that individuals with these conditions have lower levels of CD38 antigen compared to healthy individuals.

Conclusion

In conclusion, CD38 antigen has shown to be a promising drug target and biomarker for the treatment of inflammatory diseases. Further research is needed to fully understand the role of CD38 in these diseases and to develop effective treatments. By targeting CD38 antigen, researchers may be able to develop new treatments for a variety of inflammatory diseases, including cancer, autoimmune diseases, and inflammatory diseases.

Protein Name: CD38 Molecule

Functions: Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed:8253715, PubMed:7961800). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed:16690024). Has cADPR hydrolase activity (PubMed:8253715, PubMed:7961800)

The "CD38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12